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Alloimmune Retinopathy
Associated with Antibodies
to Transducin-a as
a Complication of Chronic
Graft-Versus-Host Disease
The paraneoplastic retinopathies, first described
in 1976 [1], include cancer-associated retinopathy
(CAR) and melanoma-associated retinopathy
(MAR) [2]. Affected patients present with acute,
subacute, or chronic signs and symptoms of retinal
dysfunction [3]. Findings on retinal examination in-
clude attenuated vessels, ‘‘waxy’’ disc pallor, and ret-
inal pigment epithelial mottling, although at times
the exam is normal [4,5], and there are characteris-
tically no signs of inflammation [6]. Electroretino-
grams (ERGs) are typically abnormal, and negative
waveforms are common [3]. Pathogenic retinal anti-
bodies are often found in the serum of affected in-
dividuals.
Patients with CAR usually have coexisting solid
tumors involving the lung, ovaries, or colon [7]. Serum
from affected individuals may contain antibodies torecoverin, a calcium binding protein that controls
phosphorylation of rhodopsin in both rod and cone
photoreceptors [8,9].
Recently, a series of patients has been identified
with antibodies to transducin-a, a 40-kDa photorecep-
tor G-protein naturally expressed in rods and cones
(G. Adamus et al., unpublished data). Visual transdu-
cin is activated by rhodopsin following initial photon
capture, subsequently activating PDE6, and ultimately
photoreceptor membrane hyperpolarization [10].
Transducin is also present in other tissues and associ-
ated with tumors, including melanomas and carcino-
mas [11].
Here, we report the case of a 25-year-old woman
found to have new onset retinopathy in the setting of
chronic graft-versus-host disease (cGVHD) after allo-
geneic transplant, with subsequent demonstration of
serum anti-40-kDa antibodies that react with retinal
transducin-a. To our knowledge, this is the first report
of antibodies to transducin associated with retinopathy
as a complication of cGVHD.
The patient presented in May 2003 with pancyto-
penia, and was found to have FAB M4 acute myeloge-
nous leukemia (AML) with a 6;11 translocation.
Following successful standard induction chemotherapy
and 2 cycles of consolidation, she underwent an HLA-
matched, ABOmismatched unrelated donor (MMUD)
peripheral blood stem cell transplant (PBSCT) in Sep-
tember 2003. Short-course methotrexate (MTX) and
tacrolimus were utilized for GVHD prophylaxis.
In May 2005, early cytogenetic recurrence of leu-
kemia was noted by interphase fluorescein in situ hy-
bridization (FISH). Donor lymphocyte infusion
(DLI) was administered twice, followed by reinduction
chemotherapy in mid-August 2005. After entering
a second complete remission (CR2), the patient under-
went a second allogeneic PBSCT in October 2005,
from a 10/10 matched unrelated donor (MUD).
Following her second transplant, the patient devel-
oped grade III GVHD involving the skin and liver. She
was treated successfully with prednisone. A baseline
ophthalmologic evaluation in February 2006 disclosed
mild exposure keratopathy and buried optic nerve dru-
sen. For persistent pancytopenia, the patient received
a CD34-selected marrow boost in May 2006. Subse-
quent to this, tacrolimus was switched to sirolimus
because of hyperkalemia, renal insufficiency, and mi-
croangiopathy. Diarrhea developed in August 2006,
and after a month of persistent symptoms sirolimus
was discontinued, with prednisone and hydroxychlor-
oquine used for GVHD treatment. In March 2007,
worsening liver GVHD was successfully treated with
daclizumab, rituximab, and IVIg, followed by a return
to glucocorticoids and hydroxychloroquine for
GVHD control.
The patient was seen by an ophthalmologist in
November 2007, and found to have continued
Figure 1. ‘‘Full-field’’ electroretinogram (ff-ERG) of the patient (flat line) compared to normals (contoured line). Each of the tracings demonstrates the
patient’s markedly diminished summed electrical retinal activity in response to a light stimulus. These findings represent marked loss of function of the
retinal cells, including photoreceptors (rods and cones). The oscillatory potentials measure the activity of amacrine cells in the inner retina.
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ondary exposure keratopathy. In the next 2 months,
the patient developed rapid onset of nyctalopia (night
blindness) and photopsia (perception of flashing
lights). Repeat examination in January 2008 now dis-
closed abnormal fields with peripheral constriction,
in addition to severe arteriolar attenuation, peripheral
retinal pigment epithelial mottling and marked retinal
thinning. Visual field loss occurred in a ring scotoma
pattern. An electroretinogram performed in January
2008 revealed marked reduction in rod and cone am-
plitudes (Figure 1). The patient’s serum was tested
for the presence of antiretinal antibodies by Western
blot analysis according to a previously published and
standardized method [12], and subsequently by ELISA
for transducin immunogenic alpha peptide. The pa-
tient’s peripheral blood was subsequently found to be
positive for a 40-kDa protein identified as a transdu-
cin-a retinal antibody.
The serumwas negative for antibodies to recoverin
and other retinal proteins. The patient’s symptoms
and findings were ascribed to an antibody-mediated
retinopathy as a manifestation of GVHD.Hydroxychloroquine was discontinued at this
time. Of note, the hydroxychloroquine was not
thought to be responsible for the observed findings,
but there was concern that continuation of this agent
could cause additional retinal dysfunction. The reti-
nopathy of hydroxychloroquine is a maculopathy that
produces central visual deficits, manifest as pigmentary
mottling in the macula (central retina), with a com-
pletely normal standard ERG. In contrast, this
patient’s central vision was spared and her peripheral
vision was compromised, with an ERG that showed
widespread dysfunction consistent with the fundu-
scopic findings of severe arteriolar attenuation and
peripheral pigmentary mottling.
Therapies subsequently administered to the
patient included IVIg (1 g/kg) for 2 days and repeated
monthly for 3 months; rituximab (375 mg/kg) weekly
for 4 weeks and repeated every other month for a total
of 4 cycles; plasmapheresis twice in March 2008; and
increased doses of systemic glucocorticoids. With
these treatments, the patient’s visual symptoms stabi-
lized. Currently, the patient has stable visual symp-
toms and controlled cGVHD on low doses of
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dence of AML recurrence to date.
Following stabilization of her visual symptoms,
the patient’s serum was retested for retinal antibodies
by Western blot in February of 2009, and found
to no longer be positive for the previously identified
40-kDa protein. At this point, the patient’s original
serum sample from 2008, and repeat sample from
2009, were tested for transducin immunogenic alpha
peptide; these were found to be positive in titers
of 1:16,000 and 1:2,000, respectively, confirming
a decrease in response to treatment.
There is little information available in the litera-
ture regarding treatment of antibody-mediated reti-
nopathy. Some, but not all, patients respond to
prednisone, and several local and systemic immuno-
suppressants have been used with varying degrees of
success for other patients. Visual fields and ERG can
be monitored over time, with tapering of immunosup-
pressants when stabilization is achieved; this corre-
sponds with disappearance of bands representing
pathogenic antibodies on Western blot [2].
It is possible that the transducin-a antibodies
identified in this patient were not responsible for
her retinal findings. Some antiretinal antibodies can
be found in patients with cancer who do not have
accompanying visual symptoms [12-14]. Addition-
ally, we did not have donor serum available for test-
ing, nor did we have patient serum from a time point
previous to either of her 2 transplants. However, the
appearance of highly suggestive signs and symptoms
of antibody-mediated retinopathy in our patient fol-
lowing stem cell transplant, the demonstration of an-
tibodies in her serum to a critically important
photoreceptor protein, transducin-a, and her re-
sponse to immunosuppressive therapy in the setting
of cGVHD, which paralleled a substantial decrease
in the titer of the antitransducin-a antibody, sug-
gests that transducin-a is a target protein for im-
mune reactivity during GVHD.
In summary, we describe a novel form of ‘‘alloim-
mune retinopathy’’ in a patient with extensive cGVHD
characterized by antibodies specific for the retinal
protein transducin-a. Further work is necessary to
determine if the presence of single-nucleotide poly-
morphisms (SNPs) in this protein predisposed to the
generation of immune responses in the setting of
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Autotransplantation in AL
Amyloidosis: A Flawed
Meta-analysis
The conclusions of the meta-analysis by Mhaskar
et al. [1] evaluating high-dose chemotherapy with
autotransplantation in immunoglobulin light chain
amyloidosis are compromised by the omission of
a key publication [2] and flawed analytical techniques.
The meta-analysis included 1 prospective randomized
study of 100 patients and 2 nonrandomized studies
containing a total of 49 patients. The pooled results
of these 3 studies showed superior overall survival
(OS) with conventional chemotherapy (CC) compared
to autologous hematopoietic stem cell transplantation
(AHSCT) (hazard ratio 1.79; P5 .018).
The meta-analysis excluded a study that compared
63 consecutive amyloidosis patients receiving high-
dose chemotherapy to 63 matched controls who
received conventional-intensity treatment [2]. The
groups were comparable in terms of age, left ventricu-
lar ejection fraction, peripheral nerve involvement,0.0
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Figure 1. A hypothetical scenario showing the survival of 3 different
populations of patients. There are 20 patients in each arm and 7 (35%)
have died in each arm.interventricular septal wall thickness, kidney function,
and bone marrow (BM) plasmacytosis; factors known
to influence OS. The 1-, 2-, and 4-year OS rates
from diagnosis were 89% and 71%, 81% and 55%,
and 71% and 41%, respectively, favoring AHSCT
(P \ .001). The 1-, 2-, and 4-year OS rates from
date of transplantation (cases) or initiation of therapy
(controls) were 82% and 68%, 81% and 53%, and
70% and 40% favoring AHSCT (P \ .001). These
findings remained unchanged when 7 patients receiv-
ing nonstandard treatment in the conventional-
intensity cohort were excluded. The outcome of
unmatched historic patients was even worse, confirm-
ing previous observations from the Mayo Clinic that
eligibility for AHSCT (the control group) improved
outcome [3]. However, the magnitude of the differ-
ence in outcomes between the control and AHSCT
groups provided strong suggestive evidence of the
benefit of AHSCT in appropriately selected patients
with amyloidosis [4].
The size and outcome of the Mayo study [2], had it
been included, would have changed the findings of the
meta-analysis completely, very likely showing benefit
of AHSCT over CC in amyloidosis. It would certainly
have undermined the current conclusion of the meta-
analysis—that outcome of AHSCT is inferior to CC.
The exclusion of the Mayo study on the grounds
that it was retrospective is not justifiable because
a number of the other single-arm AHSCT studies
included in the meta-analysis are not prospective stud-
ies. The authors must clarify whether the exclusion
was deliberate. A deliberate exclusion should have
been accompanied by a substantial discussion in the
meta-analysis on the totally contradictory findings of
the 2 studies. If the Mayo study was overlooked by
the authors, it suggests inadequate methodology and
quality control.
There are other serious methodologic and analyt-
ical errors in the manuscript.
Figure 3 in the paper apparently shows a forest
plot for the proportion of deaths with CC and
AHSCT. The plot, in fact, shows the combined
proportion of survivors in 7 of the 10 single-arm
AHSCT studies included in the analysis. Depiction
of a time-dependent event such as survival in this
manner is misleading and statistically inappropriate
because it ignores the time to event and the variable
duration of follow-up time in survivors. Figure 1 illus-
trates why the analytical technique chosen by the
authors to depict survival is incorrect. In this hypothet-
ical scenario, each of the 3 survival curves represents
20 patients, 7 of whom have died at the time of analysis.
Despite the dramatic outcome differences between the
groups, the technique employed by the authors would
simply show the proportion of deaths in each arm as
0.35, suggesting equivalence of outcome. This would
not be a statistically valid conclusion in a meta-analysis
